ARTICLE SUMMARY:
In this month’s “Docs of the Month” column, curated from Pathways’ Document Depot: Congress has raised more questions about FDA’s handling of COVID-19 tests in a recent letter and legislative report, adding to an accelerating drumbeat of concern that could ultimately translate into reforms.
In our “Docs of the Month” series, we spotlight key items from Pathways’ Document Depot—our running global inventory of medtech regulatory and policy documents—and provide useful details and context. This month, we spotlight a letter and a report in which members of Congress scrutinize FDA’s COVID-19 diagnostics policy.
